In order to determine the effect of GM-CSF plus G-CSF in combination in breast cancer patients receiving an effective induction regimen, we compared hematological recovery and peripheral blood progenitor cell (PBPC) mobilization according to colony-stimulating factor (CSF) support. Forty-three breast cancer patients were treated by TNCF (THP-doxorubicin, vinorelbine, cyclophosphamide, fluorouracil, D1 to D4) with CSF support: 11 patients received GM-CSF (D5 to D14); 16 patients G-CSF (D5 to D14) and 16 patients GM-CSF (D5-D14) plus G-CSF (D10-D14). Between two subsequent cycles, progenitor cells were assessed daily, from D13 to D17. The WBC count was similar for patients receiving G-CSF alone or GM-CSF plus G-CSF, but significantly greater than that of patients receiving GM-CSF alone (P Ͻ 0.001). The GM-CSF plus G-CSF combination led to better PBPC mobilization, with significantly different kinetics (P Ͻ 0.001) and optimal mean values of CFU-GM, CD34
Introduction
During the last decade, studies or meta-analyses of breast cancer suggested a positive relationship between dose intensity and treatment outcome in adjuvant 1 or neoadjuvant 2 chemotherapies, within the conventional dose range. For patients treated by primary chemotherapy, a higher total relative dose-intensity improved clinical complete response, and a significant correlation was obtained between the clinical 3 or pathological 4 response of breast tumors and overall survival rates.
Therefore, when colony-stimulating factor (CSF) became commercially available, one of its new clinical applications was to allow an increase in chemotherapy dose intensity. 5, 6 Several additional reasons have also been proposed, such as promotion of a quicker hematological recovery after high-dose chemotherapy, 7 a better quality of life, with a decrease in the intensity of severe neutropenia and a reduction in hospitalization, mucositis, and other adverse events related to high-dose chemotherapy, 8 or to mobilize peripheral blood progenitor cells (PBPC), 9 in order to obtain another source of hematological support to reduce aplasia after high-dose chemotherapy.
Since CSF has been used to reduce the duration of aplasia, CSF administration has been started between 24 and 72 h after chemotherapy and continued until the occurrence of an absolute neutrophil count of 10 × 10 9 /l of blood after the nadir. 12 In this therapeutic approach, two main CSFs are used: granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF). GM-CSF and G-CSF are produced in vivo by endothelial cells and are known to be involved in the regulation, growth and differentiation in hematopoiesis. 13 GM-CSF is a regulator of the intermediate stages of hematopoiesis, and supports the expansion and growth of both granulocytic and monocytic colony-forming units (CFU-GM). G-CSF, a later-acting cytokine, is a lineage-specific growth factor that regulates the production and function of neutrophils. Since GM-CSF and G-CSF have different biological and chronological actions, 14 the association of these cytokines in vivo could have a synergistic effect similar to that seen in in vitro studies 15, 16 but this has rarely been studied in vivo. Indeed, two in vivo studies 17, 18 have demonstrated that the combination of these two CSFs was safe and effective for PBPC mobilization. However, in these two cases, PBPC were mobilized by CSF without chemotherapy. Our schedule of GM-CSF (D5-D14) plus G-CSF (D10-D14) was derived from the findings of Winter et al, 19 in 1994. Their results showed that the addition of a second growth factor resulted in a further increase in the number of CFU-GM.
The purpose of the present work was to compare, in breast cancer patients, the effect of the combination of GM-CSF plus G-CSF with GM-CSF or G-CSF alone on PBPC mobilization and the regeneration of mature cells in the peripheral blood after induction chemotherapy. We have chosen TNCF chemotherapy, which exhibits both mobilizing 20 and specific cytotoxic 21 effects. We tested 43 patients with the TNCF regimen and studied PBPC mobilization and hematological recovery for 5 days, beginning when there were more than 1.0 × 10 9 leukocytes/l of blood. Analysis included leukocyte, red blood cell and platelet counts. PBPC were evaluated by colony-forming units granulocyte-macrophage (CFU-GM) assay, and counts of CD34 + cells and mononuclear cells in DNA synthesis (MCDS).
Patients and methods
Between January 1995 and December 1997, 43 breast cancer patients with poor prognosis were enrolled in this study. Patient characteristics are shown in Table 1 . Twenty-eight had primary (neo)adjuvant treatment and 15 had metastatic disease. Only five patients had received chemotherapy before this study. The median age of all patients was 41 years (range 31-68). Considering the first day of chemotherapy as day 1 (D1), patients were treated with 3-week cycles of TNCF (D1-D4) ( Table 2 ). After TNCF chemotherapy, patients received colony-stimulating factor support (5 g/kg once daily): G-CSF, D5-D14 (Filgrastim; Amgen, Thousand Oaks, CA, USA) or GM-CSF, D5-D14 (Molgramostim;
Schering-Plough-Sandoz, Levallois, France) or the combination of both GM-CSF (D5-D14) plus G-CSF (D10-D14). GM-CSF was given to 11 patients, G-CSF to 16 patients, and GM-CSF plus G-CSF to 16 patients. The median time of CSF administration was 10 days (range 10-15) for G-CSF, 13 days (range 10-16) for GM-CSF and 10 days for GM-CSF plus G-CSF. Consequently, the median day of last CSF administration was Table 1 Characteristics of breast cancer patients treated by TNCF chemotherapy 
D17 for GM-CSF, D14 for G-CSF and D14 for GM-CSF plus G-CSF. Leukocyte, red blood cell (RBC), and platelet counts were performed before chemotherapy and daily from the start of aplasia until the next cycle. After a TNCF cycle, from the day when white blood cells (WBC) were more than 1.0 × 10 9 /l of blood, CFU-GM, CD34
+ cells, and MCDS were evaluated daily. The median time of PBPC evaluation for each patient was 5 days: from D13 until D17. Mononuclear cell (MNC) samples for hematopoietic progenitor determinations were taken from peripheral blood and separated by Ficoll-Hypaque density gradient centrifugation (d = 1.077). Two hundred and eleven samples from 43 patients were analyzed. For four of 16 patients receiving GM-CSF plus G-CSF, we studied the products of leukapheresis.
Colony-forming units granulocyte-magrophage assay
Twenty thousand mononuclear cells in defined medium (Myelocult; Stem Cell Technology) were cultured in triplicate in semi-solid medium (Methocult; Stem Cell Technology) supplemented with rhGM-CSF (100 ng/ml; Molgramostim; Sandoz), rhG-CSF (100 ng/ml, Filgrastim; Amgen) and rhIL-3 (100 ng/ml, SDZ ILE 964; Sandoz). Plates were incubated for 14 days in a humidified atmosphere (37°C, 5% CO 2 in air). CFU-GM were scored using an inverted microscope. The count of circulating progenitor cells per milliliter of blood was determined by multiplying their frequency in culture (for 2 × 10 4 MNC) with the absolute MNC count in the same sample of peripheral blood.
Mononuclear cells expressing the surface CD34 antigen
The CD34 antigen was identified by direct immunofluorescence with a mixture of QBEnd10, Cell cycle analysis for MCDS determination was done after propidium iodide labeling of mononuclear cells, as previously described. 22 
Flow cytometry analysis
This was performed using an EPICS XL analyzer (Coulter, Miami, FL, USA). Fluorescence attributable to PE and PI was determined using excitation by an argon laser operating at 488 nm. The acquisition gate included the entire mononuclear cell populations and excluded the polymorphonuclear populations. A minimum of 50 000 events was acquired in list mode for each sample. Data analysis for CD45 and CD34 evaluations was performed using Immuno 4 software. The percent of staining was calculated in comparison to the appropriate isotype control. For each DNA histogram, the cell cycle distribution was determined by the Multicycle Software program (Phoenix, Flow Systems, San Diego, CA, USA). Circulating progenitor cells (CD34 + cells and cycling mononuclear cells) per microliter of blood were determined by multiplying their frequency by the MNC count in the same blood sample.
Expression of results and statistical analysis

Circulating CD34
+ cells, MCDS and CFU-GM were expressed as an absolute count per l or ml of peripheral blood. For the figures, results were reported as the mean Ϯ standard error mean (s.e.m.) and expressed according to the day post-chemotherapy. Differences between the mean values were evaluated by Kruskall-Wallis, multiple variance analysis (MANOVA) and matched-paired Student's tests.
Results
Toxicity
Side-effects associated with the injection of cytokines were minor, consisting chiefly of myalgia and fatigue in all patients. Six patients (18%) who received GM-CSF (three patients in the group of GM-CSF alone and three in the group of CSF combination) left the study because of mild myalgia, bone pain and low-grade temperature, and were not analyzed.
Hematological recovery
In this study, we evaluated 43 patients (Figure 1) . After TNCF chemotherapy, 11 patients received GM-CSF alone, 16 patients G-CSF alone and 16 patients GM-CSF plus G-CSF (Table 1) . No significance difference in RBC or platelet counts was observed between the three groups. For all patients, the WBC nadir typically occurred 11 days after the initiation of chemotherapy (generally 3 days before the last CSF administration) and its median duration was 4 days (range 2-6). The median value of the WBC nadir was about 0.7 × 10 9 /l and did not differ whatever the CSF adminis- tered. WBC recovery Ͼ1.0 × 10 9 /l of blood occurred on a median of day 12 (D12) for G-CSF, D13 for GM-CSF plus G-CSF and D14 for GM-CSF after the initiation of chemotherapy. For patients receiving GM-CSF, WBC regeneration was significantly different from the two other groups (P Ͻ 0.001). Indeed, WBC and MNC increased slowly until the last day of GM-CSF administration. Conversely, patients receiving G-CSF or the combination of both CSFs, had a similar WBC and MNC recovery. The maximum WBC was at D15 and reached respectively 18.5 (1-43.6) × 10 9 /l for patients receiving G-CSF and 16.6 (range 7.2-53) × 10 9 /l for patients receiving GM-CSF plus G-CSF.
Kinetics of PBPC mobilization
From D13 to D17, we studied daily the PBPC recruitment after TNCF chemotherapy and CSF administration by evaluation of CD34 + cells, mononuclear cells in DNA synthesis, and CFU-GM (Figure 2 ). The profile of PBPC kinetics was significantly different between the three groups (P Ͻ 0.001). For patients receiving GM-CSF, the mean number of CFU-GM, CD34 (Table 3) . For the patients receiving G-CSF, the peak number of progenitor cells occurred generally on D15: 9417 × 10 3 CFU-GM/l, 164 × 10 6 CD34 + cells/l and 137 × 10 6 MCDS/l. For patients who received both factors, PBPC mobilization was significantly better than that of the two other groups (P Ͻ 0.001). The mean value of progenitor cells on D15 was: 17 616 × 10 3 CFU-GM/l, 250 × 10 6 CD34 + cells/l and 244 × 10 6 MCDS/l. Compared to GM-CSF alone or G-CSF alone, PBPC mobilization on D15 was four-fold and two-fold greater with the combination of GM-CSF plus G-CSF.
Discussion
For most cancer treatments, one major obstacle in delivering optimal doses of chemotherapy agents is the hematopoietic toxicity. The CSFs are now well known to be involved in the regulation, growth, and differentiation of hematopoiesis. Three hematopoietic growth factors are currently commercially available for clinical use: 13 GM-CSF, G-CSF and erythropoietin. Studies in vitro have shown that GM-CSF acts earlier than G-CSF. 15, 16 In a previous study, we have shown a specific cytotoxic effect on breast tumor 21 and at the same time, mobilization of PBPC 20 after TNCF treatment and G-CSF. In the present work, we looked for a synergistic effect of GM-CSF and G-CSF to improve hematological recovery between two TNCF cycles and to mobilize a sufficient number of PBPCs in one leukapheresis. To reach this goal, we evaluated the regeneration of mature cells and PBPC mobilization by enumeration of CFU-GM, CD34
+ cells and MCDS from the peripheral blood of breast cancer patients. These patients received TNCF chemotherapy prior to GM-CSF alone, G-CSF alone, or a combination of both CSFs. For all patients, a short period of aplasia (generally 4 days) was followed by hematological reconstitution. In patients receiving GM-CSF alone, the hematological recovery was slower than with G-CSF or G-CSF plus GM-CSF. Consequently, the duration of GM-CSF administration was longer (13 days) compared to the two other groups (10 days) and the hematological recovery of patients receiving G-CSF or the combination of both CSFs occurred more rapidly than for patients receiving GM-CSF alone. Nevertheless, the evaluation of PBPC from day 13 to day 17, showed significant differences between the three groups (P Ͻ 0.001). In this study, whatever the method of PBPC evaluation used, PBPC mobilization showed an optimal median level on day 15 for patients receiving G-CSF alone or GM-CSF plus G-CSF and on day 17 for patients receiving GM-CSF. However, the magnitude of the PBPC peak was related to the CSF administration: their recruitment in patients receiving GM-CSF plus G-CSF was two-fold greater compared to patients receiving G-CSF, and four-fold greater compared to patients receiving GM-CSF.
This synergistic effect of combined GM-CSF and G-CSF, was found in both previous in vivo studies. 17, 18 In these two cases, the PBPC mobilization was performed after CSF administration without chemotherapy: Lane et al 17 published in 1995 the results of CFU-GM and CD34
+ obtained in the apheresis product of five normal donors and Winter et al, 18 published in 1996 the results of CFU-GM and CD34
+ cells obtained on the apheresis product of five cancer patients who received several GM-CSF and G-CSF combinations. Consequently, it was difficult to compare our results with theirs, because the chemotherapy prior to CSF support is more effective for mobilization. 23 The same consideration applies to the results of Spitzer et al, 24 who had somewhat different mobilization protocols. Closer to our procedure, To et al, 251 in 1994, showed that the CD34 + cell phenotype was different according to the mobilization protocols (CSF alone, or with chemotherapy) and Lane et al, 26 in 1999, showed that mobilization with the GM-CSF regimen gave more immature cells (CD34
). In our study, the level of progenitors obtained in peripheral blood for the patients receiving the combination of both CSFs was optimal on day 15. So, four out of 16 patients treated by TNCF and GM-CSF plus G-CSF, had PBPC collection by leukapheresis on D15. Median levels of MNC, CD34
+ cells and CFU-GM were respectively 4.8 (4.6-7. Our results were also comparable to a recent randomized study analyzing the mobilization of PBPC after cyclophosphamide and various combinations of G-CSF and SCF. 31 Another advantage of our protocol is to combine a breastspecific and efficient chemotherapy allowing sufficient PBPC recovery without the need of a special cycle (etoposide-cyclophosphamide) for mobilization.
In conclusion, our results suggest that for induction TNCF chemotherapy, injection of G-CSF alone is adequate to obtain a rapid hematological recovery. However, the administration of GM-CSF and G-CSF after TNCF regimen would produce a predictable and greater PBPC mobilization on day 15. Now, it would be interesting to compare in a clinical trial the quality of PBPC (progenitors and stem cells) obtained by the three schemes of CSF administration and to compare the short-term and long-term hematological recoveries. A second point of interest of the GM-CSF plus G-CSF association to collect PBPC could be a better PBPC collection in patients previously treated by numerous lines of chemotherapy.
